Dianthus Therapeutics, Inc.DNTHNASDAQ
Loading
EV to Sales: Premium ValuationElevated
Percentile Rank100
3Y CAGR+705.1%
Studio
Year-over-Year Change

Enterprise value to sales ratio

3Y CAGR
+705.1%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
521.9x
Strong expansion
Streak
2 yr
Consecutive growthElevated
PeriodValueYoY Change
2025740.57+555.0%
2024113.06+508.9%
2023-27.65-2048.8%
20221.42-98.1%
202175.73-
20200.00-
20190.00-
20180.00-
20170.00-
20160.00-